Geron (GERN) Competitors $1.43 +0.02 (+1.42%) Closing price 04:00 PM EasternExtended Trading$1.42 0.00 (-0.35%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. ALKS, LGND, FOLD, BCRX, NVAX, CLDX, INVA, DVAX, MNKD, and OPKShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. Geron vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Novavax Celldex Therapeutics Innoviva Dynavax Technologies MannKind OPKO Health Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Which has stronger valuation & earnings, GERN or ALKS? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M11.85-$174.57M-$0.13-11.00Alkermes$1.56B3.07$367.07M$2.0813.91 Does the media prefer GERN or ALKS? In the previous week, Alkermes had 13 more articles in the media than Geron. MarketBeat recorded 23 mentions for Alkermes and 10 mentions for Geron. Geron's average media sentiment score of 1.16 beat Alkermes' score of 0.59 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GERN or ALKS? Geron currently has a consensus target price of $4.19, suggesting a potential upside of 192.83%. Alkermes has a consensus target price of $41.08, suggesting a potential upside of 42.01%. Given Geron's higher possible upside, equities research analysts clearly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do institutionals and insiders believe in GERN or ALKS? 73.7% of Geron shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 7.4% of Geron shares are held by company insiders. Comparatively, 4.4% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is GERN or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Geron's net margin of -53.52%. Alkermes' return on equity of 24.86% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-53.52% -31.37% -16.01% Alkermes 23.15%24.86%17.14% Which has more risk & volatility, GERN or ALKS? Geron has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. SummaryAlkermes beats Geron on 11 of the 16 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$899.60M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-11.0021.0831.2626.59Price / Sales11.85400.78464.64173.43Price / CashN/A44.6737.7359.36Price / Book3.498.0910.046.68Net Income-$174.57M-$54.08M$3.27B$265.59M7 Day PerformanceN/A2.25%3.17%3.42%1 Month Performance24.35%3.41%4.34%1.09%1 Year Performance-68.29%18.61%44.12%23.84% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron2.9718 of 5 stars$1.43+1.4%$4.19+192.8%-69.7%$899.60M$76.99M-11.00229ALKSAlkermes4.6713 of 5 stars$29.06+0.3%$41.08+41.4%+3.8%$4.78B$1.56B13.971,800LGNDLigand Pharmaceuticals4.0888 of 5 stars$157.31+1.3%$157.00-0.2%+49.6%$3.04B$167.13M-39.3380Positive NewsAnalyst ForecastFOLDAmicus Therapeutics4.3122 of 5 stars$7.60+2.7%$16.22+113.5%-33.2%$2.28B$528.29M-63.33480Positive NewsBCRXBioCryst Pharmaceuticals4.1583 of 5 stars$8.38flat$16.70+99.3%+3.5%$1.76B$557.51M-46.55530Positive NewsNVAXNovavax4.5408 of 5 stars$7.63-12.7%$15.57+104.1%-32.0%$1.42B$682.16M3.351,990News CoverageAnalyst ForecastGap UpHigh Trading VolumeCLDXCelldex Therapeutics1.845 of 5 stars$22.02+5.4%$46.67+111.9%-40.8%$1.39B$7.02M-7.32150News CoverageINVAInnoviva4.4843 of 5 stars$19.97+0.1%$42.75+114.1%+3.8%$1.26B$358.71M64.42100Positive NewsDVAXDynavax Technologies4.6929 of 5 stars$10.95+5.1%$24.33+122.2%-8.5%$1.22B$277.25M-23.80350High Trading VolumeMNKDMannKind3.2807 of 5 stars$3.94-0.8%$9.71+146.6%-16.0%$1.22B$285.50M35.82400News CoverageAnalyst ForecastGap DownOPKOPKO Health4.4255 of 5 stars$1.38-0.7%$2.75+99.3%-13.9%$1.10B$664.03M-5.522,997Positive News Related Companies and Tools Related Companies ALKS Competitors LGND Competitors FOLD Competitors BCRX Competitors NVAX Competitors CLDX Competitors INVA Competitors DVAX Competitors MNKD Competitors OPK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access